Factor VII deficiency: do all need replacement for cardiac surgery?

Area of Science:

• Cardiology
• Hematology
• Surgical Management

Background:

• Recombinant factor VIIa (rFVIIa) is a standard treatment for factor VII deficiency during cardiac surgery.
• Overuse of rFVIIa carries a risk of thromboembolic complications.
• Accurate prediction of the need for rFVIIa supplementation remains a clinical challenge.

Observation:

• A 53-year-old male patient with factor VII deficiency (activity 15.2%, INR 2.9) presented with critical coronary anatomy.
• The patient underwent complex cardiac surgery (coronary artery bypass) and a subsequent thoracotomy with decortication.
• Successful surgical management was achieved without the administration of rFVIIa.

Findings:

• Standard laboratory tests, including prothrombin time/international normalized ratio (PT/INR) and factor VII activity assays, may not reliably indicate the necessity for rFVIIa therapy.
• Thromboelastography (TEG) also did not predict the requirement for replacement therapy in this specific case.
• This case highlights potential limitations of current diagnostic tools in guiding rFVIIa use.

Implications:

• Current diagnostic methods may not adequately predict the need for rFVIIa in patients with factor VII deficiency undergoing major surgery.
• Clinical decision-making for rFVIIa supplementation may require a more nuanced approach beyond standard laboratory values.
• Further research is needed to identify more reliable predictors for rFVIIa therapy in surgical patients with factor VII deficiency to optimize treatment and minimize risks.